A detailed history of Sectoral Asset Management Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Sectoral Asset Management Inc holds 28,593 shares of CYTK stock, worth $1.39 Million. This represents 1.26% of its overall portfolio holdings.

Number of Shares
28,593
Previous 36,883 22.48%
Holding current value
$1.39 Million
Previous $2 Million 24.47%
% of portfolio
1.26%
Previous 0.99%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.22 - $60.16 $424,613 - $498,726
-8,290 Reduced 22.48%
28,593 $1.51 Million
Q2 2024

Aug 13, 2024

SELL
$47.86 - $75.05 $272,802 - $427,785
-5,700 Reduced 13.39%
36,883 $2 Million
Q1 2024

May 14, 2024

BUY
$63.75 - $108.06 $2.27 Million - $3.84 Million
35,570 Added 507.2%
42,583 $2.99 Million
Q4 2023

Feb 14, 2024

SELL
$26.88 - $83.49 $2.99 Million - $9.29 Million
-111,290 Reduced 94.07%
7,013 $585,000
Q3 2023

Nov 14, 2023

BUY
$29.46 - $36.61 $35,941 - $44,664
1,220 Added 1.04%
118,303 $3.49 Million
Q2 2023

Aug 11, 2023

BUY
$32.62 - $40.75 $1.08 Million - $1.35 Million
33,233 Added 39.63%
117,083 $3.82 Million
Q1 2023

May 12, 2023

BUY
$33.36 - $45.71 $13,344 - $18,284
400 Added 0.48%
83,850 $2.95 Million
Q3 2022

Nov 10, 2022

SELL
$38.54 - $54.52 $21,197 - $29,986
-550 Reduced 0.65%
83,450 $4.04 Million
Q2 2022

Aug 15, 2022

BUY
$33.93 - $48.92 $475,020 - $684,880
14,000 Added 20.0%
84,000 $3.3 Million
Q1 2022

May 10, 2022

BUY
$29.74 - $46.0 $2.08 Million - $3.22 Million
70,000 New
70,000 $2.58 Million
Q2 2019

Aug 14, 2019

SELL
$7.95 - $11.25 $123,876 - $175,297
-15,582 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$6.4 - $9.85 $99,724 - $153,482
15,582 New
15,582 $153,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.57B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Sectoral Asset Management Inc Portfolio

Follow Sectoral Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sectoral Asset Management Inc with notifications on news.